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Abstract
Background: Mechanisms influencing breast cancer (BC) development and recurrence include hyperglycemia,
hyperinsulinemia, high insulin-like growth factor-1, high circulating estrogen, inflammation and impaired cellular
differentiation/apoptosis. A lifestyle program that targets all the above mechanisms may be warranted. Low
glycemic index (GI) foods produce lower post-prandial glucose and insulin responses and have been associated
with lower BC risk. Moderate physical activity post-diagnosis reduces BC recurrence and mortality, partly explained
by reduced insulin and estrogen levels. Vitamin D increases cell differentiation/apoptosis and high serum vitamin D
levels improve BC survival. Yet no trial has evaluated the combined effect of a low GI diet, moderate physical
activity and vitamin D supplementation on BC recurrence in the context of a Mediterranean lifestyle setting.
Methods: Women (30-74 yr) who had undergone surgery for primary histologically confirmed BC (stages I-III)
within the previous 12 months, in cancer centres in Italy, will be randomized to follow, for a maximum of
33 months, either a high intensity treatment (HIT) composed of low GI diet + exercise + vitamin D (60 ng/mL serum
concentration) or a lower intensity treatment (LITE) with general advice to follow a healthy diet and exercise
pattern + vitamin D to avoid insufficiency. Both interventions are on a background of a Mediterranean diet.
Considering a 20% recurrence rate within 3 years for BC cases and a predicted rate of 10% in the HIT group, with
power of 80% and two-sided alpha of 0.05, the subject number required will be 506 (n = 253 in each arm). Clinic
visits will be scheduled every 3 months. Dietary and exercise counselling and vitamin D supplements will be given
at each clinic visit when blood samples, anthropometric measures and 7-day food records will be collected.
Discussion: DEDiCa study aims to reduce BC recurrence in women with BC using a lifestyle approach with
additional vitamin D and to investigate possible cardio-metabolic benefits as well as epigenetic modifications
according to lifestyle changes. Given the supporting evidence and safety of the components of our intervention we
believe it is feasible and urgent to test it in cancer patients.
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Background
Breast cancer (BC) is the most common cancer in
women and the 5-year survival rate in Europe is 82%
suggesting a considerable residual risk [1]. BC is associ-
ated also with other chronic conditions including type
two diabetes which may increase the risk of BC recur-
rence [2–4] and many BC patients are at increased risk
for cardiovascular disease (CVD) [5, 6]. Mechanisms of
BC appear to be linked to sex hormones, impairment in
glucose metabolism, hyperglycemia, hyperinsulinemia,
insulin-like growth factors (IGF), inflammation, oxida-
tive stress and impaired cell apoptosis [7, 8]. Current
advice to BC survivors suggests adopting cancer preven-
tion strategies [8, 9], however there is no consensus on
the effectiveness of lifestyle programs in women with BC
[10–12] mostly due to lack of sufficient evidence [13].
The rationale for the study is to target several mecha-
nisms of cancer suppression or proliferation, with a
healthy diet and exercise program, to avoid low vitamin
D levels in order to obtain maximal efficacy of the life-
style program, and concomitantly to offer maximal CVD
and diabetes protection. Dietary carbohydrates are the
main food components to affect glycemia and insuline-
mia. The glycemic index (GI) is able to capture the dif-
ference between those that increase glycemia the most
(high GI foods) and those that increase it the least (low
GI foods) [14]. Low GI foods lower the glycemic and
insulinemic potential of the diet and have been shown to
reduce the risk of several cancers particularly diabetes-
related cancers including BC [15–18] and some evidence
suggests they also correlate with lower recurrence [19].
Furthermore, low GI diets have been inversely associated
with risk of type two diabetes [15, 20, 21] and CVD
[22, 23] and favourably modified blood glucose [24–26],
blood lipids [27], inflammatory markers [28], oxidative
damage [29], body weight [30] and IGF binding pro-
teins [31], all factors relevant to carcinogenesis, dia-
betes and CVD. Our previous studies in Italy have
shown significant risk reduction of 40% with a low GI
diet compared to a high GI diet in BC primary pre-
vention [18]. Physical activity is one of the mainstays
of primary prevention of cancer and it is also in-
cluded in guidelines for BC survivors (at least 150 mi-
nutes per week) mainly to reduce complications such
as lower muscle strength and risk of depression [13].
However, physical activity after BC diagnosis has also
been shown to reduce the risk of BC mortality by
40–50% particularly when it is of moderate intensity
such as 30 minutes of brisk walking per day [32–35]
an effect possibly modulated partly by insulin econ-
omy improvements in reduced insulin, insulin-like
growth factors and estrogen levels [36].
To maximize lifestyle changes it may be useful to
avoid vitamin deficiencies, particularly vitamin D defi-
ciency which has been linked to higher breast cancer
risk [37, 38]. Vitamin D alters genes implicated in
cellular growth, affecting proliferation, apoptosis, dif-
ferentiation, angiogenesis, invasion and metastasis [37].
Preliminary studies suggest that normal-high ranges of
serum vitamin D levels improve BC survival [39, 40].
Low glycemic index diet, exercise and vitamin D in-
take, in addition to determining metabolic changes
and benefits for cancer patients, may be able to
change the tumor microenvironment and lead to epi-
genetic modifications [41–44]. In this context, micro-
RNAs (miRNAs), small noncoding RNA molecules,
may play a fundamental role in modulating gene ex-
pression and breast cancer progression [45, 46]. The
evaluation of circulating miRNAs is useful to identify
the change of specific miRNAs involved in cancer
pathways and predict the development of recurrence
in breast cancer patients.
A lifestyle program that targets all the above mecha-
nisms may be warranted. To our knowledge no trial has
evaluated the combined effect of a lifestyle program with
a healthy diet focusing on low GI, additional physical ac-
tivity and supplemental vitamin D on BC recurrence and
complications in the context of a Mediterranean dietary
setting.
Methods/Design
Aims and objectives
DEDiCa study aims primarily at reducing BC recur-
rence in women with BC using a lifestyle approach
with additional vitamin D. The primary objective of
DEDiCa study is to determine the effect of a 33-
month program combining advice on diet, exercise
and supplemental vitamin D, on reducing BC recur-
rence rates or increasing disease-free survival (DFS).
Secondary objectives are to improve markers of dia-
betes risk and management for those who already
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have diabetes, to improve cardiometabolic health and
quality of life (QoL) and to investigate whether
changes in microRNA correlate with changes in
lifestyle.
Study design
This is a randomized clinical trial targeting women with
BC stages I-III within 12 months from BC surgery (see
Tables 1 and 2 for details). The study involves at least
five cancer centers in Italy (Table 3) and it started on
Oct 10th, 2016. Consenting participants are randomized
to either a high intensity program (HIT) or a lower in-
tensity program (LITE, positive control). The endpoints
will be assessed at baseline and every three months until
the end of the study (Fig. 1).
To improve compliance participants on both sides will
be followed equally with blood tests and clinic visits and
will be equally offered general advice on a healthy Medi-
terranean diet and physical activity, step counters and
vitamin D supplements to avoid insufficiency. Partici-
pants in the HIT group will additionally receive dietary
counselling on how to reduce the GI of their diet, pack-
ages of pasta, more in-depth advice on exercise and
more vitamin D supplements compared to the LITE
group.
This study was approved by the ethic board of the
Italian Medicine Agency (AIFA), and of each recruit-
ing hospital: National Cancer Institute “Fondazione
Giovanni Pascale” in Naples, Azienda Ospedaliera per
l’Emergenza Ospedale Cannizzaro in Catania, Azienda
Ospedaliera Universitaria Policlinico “G. Martino” in
Messina for San Vincenzo Hospital of Taormina,
Comitato Etico Campania Centro ASL NA1 Centro
for Clinica Mediterranea in Naples. The study has
been registered with ClinicalTrials.gov (registration
date and number: May 11, 2016; NCT02786875).
Participants
Women who had undergone surgery for primary histo-
logically confirmed BC, stages I-III (see Tables 1 and 2
for details), within the previous 12 months in cancer
centres in Italy, who are between the ages 30–74 years
and have no contraindications to participate in this study
will be eligible to participate. Eligibility is confirmed by
central reviewing of medical records and pathology re-
ports. The inclusion and exclusion criteria are summa-
rized in Table 1. To participate in the study each
potential participant is required to read and sign the
study information/consent form at baseline.
Recruitment and randomization
Eligible participants are recruited in five oncologic cen-
tres in Italy (four in Southern Italy and one in Northern
Italy). Details of the recruiting centres can be found in
Table 3. Eligible participants are contacted either by
phone or during one of their follow-up visits and offered
to hear more about the study during an information ses-
sion (either group session or a one-to-one session to ac-
commodate all needs). Eligible participants are explained
the study details and are given an informed consent
document to take home which they bring back at the
baseline visit. At the baseline visit, after obtaining writ-
ten consent the participant is sent for a blood test and
Table 1 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
1. Women with primary diagnosis
of histologically confirmed
breast cancer (T1 with Ki67≥
30%, T2, T3 without metastasis)
within 12 months from
diagnosis.
2. Age ≥ 30 and < 75 years.
3. Patients who are able to
comprehend and are willing to
sign the consent form and are
able to adhere to the protocol
including scheduled clinic visits
and assigned treatment.
1. Patients who do not possess the
inclusion criteria for this study.
2. Patients with sarcoidosis or other
granulomatous diseases or with
hypercalcemia (Ca > 11 mg/dL).
3. Patients with any previous or
current concomitant malignant
cancer.
4. Pregnant or lactating women.
5. Patients with AIDS diagnosis
6. Patients with severe renal
insufficiency
7. Patients with kidney stones
(nephrocalcinosis or
nephrolithiasis)
8. Patients participating in other
lifestyle clinical trials
Table 2 Details of inclusion criteria n. 1
Stage Primary Tumor Lymph nodes Metastasis Ki-67
I T1b, T1c N0 M0 ≥30%
IIA T1a, T1b, T1c
T2
N1
N0
M0
M0
any
IIB T2
T3
N1
N0
M0
M0
any
IIIA T1a, T1b, T1c
T2
T3
N2
N2
N1, N2
M0
M0
M0
any
IIIC T1a, T1b, T1c
T2
T3
N3
N3
N3
M0
M0
M0
any
Table 3 List of recruiting centres in Italy
Recruiting centres
• Coordinating Centre: National Cancer Institute Fondazione G. Pascale
(Napoli);
○ Via Mariano Semmola – 80131 Napoli
○ Tel: 081/5903395
○ Email: epidemiologia@istitutotumori.na.it
○ www.istitutotumori.na.it/
• Clinica Mediterranea, Senology Unit; Via Orazio, 2–80122 Napoli;
www.clinicamediterranea.it/
• Cannizzaro Hospital, Senology Unit; Via Messina, 829–95126 Catania;
www.aocannizzaro.it/
• San Vincenzo Hospital of Taormina, Oncology Unit; Via Sirina, 98039
Taormina (Messina); www.oncologiataormina.it/
• National Cancer Institute CRO Aviano; Via Franco Gallini, 2–33081
Aviano (Pordenone); www.cro.it
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other measurements, is randomized to one of the two
arms of the study, receives the advice on the program
according to her randomization arm and is given the
next appointment slip. Participants are contacted by
phone monthly for the first three months and once be-
tween visits afterwards. Study visits are scheduled every
3 months until end of study (33 months).
Randomization is done electronically in real time for
all recruiting centres and is stratified by stage (I/IIA vs.
IIB/IIIA) and age (<50 yrs or ≥50 yrs) at diagnosis and is
based on a permuted block design with block size of 4.
Stratification by stage and age is done because we expect
these variables to affect the outcomes. To prevent any
possible study bias the randomization sequence will be
done off-site by a third party statistician (Contract
Research Organization, Naples, Italy) who will not have
contacts with the study participants. The PI is blinded to
the randomization of the study participants but not the
staff involved in the clinic visits.
Interventions
Eligible and consenting subjects are randomized to ei-
ther one of the two treatment programs (higher or lower
intensity):
Higher intensity (HIT) arm (test): low GI diet +
exercise + vitamin D.
1) All carbohydrate foods advised will be low GI
choices (GI < 70, on the bread scale), e.g. legumes,
pasta al dente, barley, low GI rice, low GI bread, oat,
apples, oranges, berries, avocado and nuts.
2) Brisk walk of at least 30 min per day (or
approximately 5000 steps) more than the habitual
physical activity.
3) Vitamin D supplement (cholecalciferol) up to
4000 IU/day to reach the upper end of normal blood
levels of 25(OH)D (60 ng/ml).
Lower intensity (LITE) arm (positive control): general
recommendations for a healthy diet and physical
activity. Vitamin D (cholecalciferol) will be given only if
hypovitaminosis D is detected to bring blood levels up
to normal ranges of 30 ng/mL.
Both groups will be counselled to follow a healthy
Mediterranean diet (≥5 servings vegetable/fruit per
day, ≤1 serving red meat/cold cuts per week, <7%
saturated fat).
Treatment evaluations are conducted every three
months at each clinic visit and include all three compo-
nents of the treatment (diet, exercise, vitamin D). Seven-
day food records is collected from each patient which is
filled a week before the clinic visit. The information in
the food record is reviewed by the nutritionist staff with
the patient and subsequently inserted in a diet analysis
program (WinFood Medimatica, Version 3.9.0). Daily
means of GI, energy intake, macro- and micro-nutrients
and food groups will be obtained from WinFood and
periodically evaluated to ensure adherence to the dietary
advice. The physical activity component is measured
with a step counter with 7-day memory (OMRON Walk-
ing Style IV) and with a questionnaire. Participants bring
the step counter back at each clinic visit and the 7-day
values are recorded by the research staff. Vitamin D is
evaluated by blood analysis of 25(OH)D every three
months, the dose reviewed at each clinic visit and chan-
ged if necessary to reach the group target (Table 4). QoL
is measured with questionnaires specifically made for
cancer patients (EQ-5D-3 L, EORTC QLQ-C30 e
EORTC QLQ-BC23) [47–49].
Outcome measures
Figure 1 depicts the timing and frequency of all study
measures. Blood analyses, blood pressure, anthropomet-
ric measurements and 7-day food records are taken at
Fig. 1 Schematic representation of DEDiCa study protocol
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baseline and every 3 months afterwards until end of
study (up to 33 months). Complete blood analyses are
done at baseline, 1 year and end of study while blood
analysis pertinent to the treatment are done every three
months (Table 5). The primary outcome is the percent-
age of patients alive at end of study without BC
recurrence (disease in the same or opposite breast or
any metastasis). The primary outcome is assessed at
each collaborating centre by the collaborating oncologist
and confirmed by hospital pathological results which are
communicated to the coordinating centre. Secondary
end points include glycemic control including blood glu-
cose and glycated hemoglobin (HbA1c), cardiometabolic
variables including body weight, waist circumference,
body mass index (BMI), blood pressure, C-reactive pro-
tein (CRP) and blood lipids, hormonal measures includ-
ing insulin, insulin-like growth factor-1 (IGF-1),
estradiol, testosterone and sex hormone binding globulin
(SHBG), and epigenetic markers (microRNA). Program
adherence and any difficulty noticed, medications and
medication changes, as well as any unusual or adverse
events, including illness or stressful issues, that occurred
since the last clinic visit are recorded in detail.
Blood samples and all information regarding the pa-
tient are sent to the coordinating centre where blood
samples are centrally analyzed and information entered
electronically and statistically analyzed for the interim
and end of study reports.
Biochemical analyses
Serum vitamin D and IGF-1 are analyzed using DiaSorin
kits on Liaison XL analyzer (DiaSorin) by chemilumines-
cent method (CLIA). The HbA1c value is analyzed using
whole blood collected in EDTA Vacutainer tubes
(Vacutainer; Becton, Dickinson and Co) by a turbidimet-
ric inhibition latex immunoassay (TINA QUANT Roche
Diagnostics) on Cobas C6000 analyzer (Roche). Serum
glucose, total cholesterol, triglycerides, high-density lipo-
protein cholesterol (HDL-C), low-density lipoprotein
cholesterol (LDL-C), are measured using reagents and
analyzer (Cobas C6000) by Roche Diagnostics according
to the manufacturer’s instructions. Serum insulin, estra-
diol, testosterone and SHBG are performed on the same
analyzer by electro-chemiluminescent method (ECLIA).
Nephelometric quantification of CRP is performed on
BNP ProSpec nephelometer (Siemens Healthcare Diag-
nostics) according to the manufacturer’s instructions.
Serum samples are obtained by blood collected in
Vacutainer tubes without anticoagulant (Becton, Dickinson
and Co) and analyzed within 24 hours. All analytes are
measured in the coordinating hospital routine analytical la-
boratory undergoing quality control procedures.
MicroRNA Analysis
Previous studies have demonstrated that microRNAs
(miRNAs) are frequently dysregulated in human cancers,
including BC [50, 51] and may be modified by the gly-
cemic load of the diet [41]. Computational models are
important for the understanding of biological systems
[52]. The following are the procedures to identify and
Table 4 Vitamin D algorithm
Blood levels
(ng/ml)
Oral dose (IU) Treatment duration
Group A (target: 60 ng/ml):
< 10 75 000 at study visit
+4000/day
3 months
then re-evaluate
> 10-20 50 000 at study visit
+4000/day
3 months
then re-evaluate
> 20-30 25 000 at study visit
+4000/day
3 months
then re-evaluate
> 30 4000/day 3 months
then re-evaluate
60-80 change to 1000 IU/day 3 months
then re-evaluate
Group B (target: 30 ng/ml):
≤ 10 100 000 at study visit Re-evaluate after 3 months
≤ 20 75 000 at study visit Re-evaluate after 3 months
> 20-25 50 000 at study visit Re-evaluate after 3 months
> 25-29 25 000 at study visit Re-evaluate after 3 months
≥ 30 0 Re-evaluate after 3 months
Table 5 Blood analyses performed during the study
Parameters Baseline, 12 mo and study end Every 3 months
25(OH)D x x
Calcium x x
Glucose x x
HbA1c x x
Insulin x
Triglycerides x
Total Cholesterol x
LDL-C x
HDL-C x
AST/ALT x
CRP x
Estradiol x
Testosterone x
SHBG x
IGF-1 x
microRNA x
For future analyses x x
AST/ALT: aspartate transaminase/alanine transaminase, CRP: C-reactive protein,
HbA1c: hemoglobin A1c, HDL-C: high density lipoprotein cholesterol, IGF-1:
insulin-like growth factor-1, LDL-C: low density lipoprotein cholesterol, SHBG:
sex hormone binding globulin, 25(OH)D: 25-hydroxyvitamin D.
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analyze miRNA. These analyses will be conducted at the
Laboratory of the Biomedical Sciences Department at
the University of Catania (Italy).
Identification of plasma miRNA in BC
Plasma samples are randomly selected for the analysis
by the Human Serum & Plasma miScript miRNA PCR
Array (Qiagen) that profiles the expression of 84 miR-
NAs. In this phase, miRNA expression patterns are ana-
lyzed in BC patients according to the lifestyle and
dietary intake.
Circulating microRNA analysis
miRNAs can be easily purified from a number of patient
body fluids. Several studies shown that miRNAs were
present in serum and plasma and easily detectable by a
sample of peripheral blood. Circulating miRNAs may be
important players in the formation of the tumor micro-
environment and metastatic evolution by promoting epi-
thelial to mesenchymal transition (EMT) of tumor cells.
RNA and miRNAs fraction are extracted from 200 μL of
plasma are isolated by miRNeasy Serum/Plasma Kit
(Qiagen, Hilden, Germany) according to the manufac-
turer’s recommendations Extracted miRNAs are reverse
transcribed into cDNA and analyzed by miScript SYBR
Green PCR Kit (Qiagen).
Validation of circulating miRNAs in BC tissues
Data obtained in the previous two steps above are vali-
dated in tumor tissue samples to confirm the origin
source of the circulating miRNA previously identified.
miRNAs and epithelial mesenchymal transition (EMT)
miRNAs, a class of small non-coding RNA molecules
that post-transcriptionally regulate gene expression, are
attractive candidates for regulating stem cell self-
renewal, cell fate decisions and cell plasticity. For this
reason, miRNAs analysis is carried out to shed light on
the post-transcriptional control of EMT and stemness.
Analysis of EMT genes
Publicly available gene expression datasets are analyzed
to identify pathways involved in EMT. For this reason a
comparative analysis of expression of master regulators
of EMT genes (Beta-Catenin, OPN, Twist1/2, Snail1/2,
Zeb1/2, N-cad, Vim, E-cad and NGAL) will be per-
formed. GSEA (Gene Set Enrichment Analysis http://
broad.mit.edu/gsea) will assess whether the potential
pathways involved in EMT, identified in the previous
analysis, will be confirmed using a different computa-
tional approach. The key genes, representing the highly
connected hubs in the identified networks, are assessed
by qRT-PCR and IHC on selected archival tumor series
to determine their diagnostic and prognostic value
according to clinical information, lifestyle and dietary
intake.
MiRNAs and their role in modulating EMT
Validated miRNAs are analyzed by in silico approaches
(miRanda, miRbase, TargetScan) to evaluate if EMT
genes previously analyzed are included among their pu-
tative target genes. miRNAs here identified and their pu-
tative target genes are analyzed in BC tumor tissue,
positive for canonical mesenchymal markers, such as
Vimentin and N-cadherin. Evaluation of EMT markers
are carried out by IHC followed by laser micro-
dissection. Further functional experiments are per-
formed to validate in silico considerations.
Risk recurrence in BC by computational modeling
The development of a computational model based on
agent based modelling, differential equations or Petri
nets could lead to a validated tool able to predict the ef-
ficacy of the dietary regimen. The model is fit with data
coming from the diet regiment components, diet effects,
life style, and from plasma miRNAs analysis. miRNAs
expression allows the model to be tuned to find evi-
dences that may be relevant to predict the time and the
probability of recurrence risk.
Sample size
Considering a 20% recurrence rate within 3 years in
most collaborating centres for BC cases specified in
Table 2, and a predicted rate of 10% in the high intensity
arm, with power of 80% and two-sided alpha of 0.05, the
number of subjects are 506 (n = 253 in each arm).
Statistical analyses
All randomized patients will be analysed considering the
“intention-to-treat” principle (ITT analysis). Results will
be expressed as percentages or means ± SEM or 95%
confidence intervals (CI).
Primary analyses
The primary analyses will assess the between-treatment
difference in BC recurrence measured as disease-free
survival (DFS), calculated as the percentage of patients
alive without recurrence of disease at study end (up to
33 months from randomization). BC recurrence is de-
fined as the relapse of the disease or metastasis either in
the same breast (including new positive lymph nodes),
or the opposite breast or in distant organs. The duration
of DFS in patients lost at follow-up will be censured at
the date of the last day the patient was considered free
of disease. Between-treatment differences in DFS will be
analyzed by log-rank test. Kaplan-Meier curves will be
provided to estimate median DFS and 95% CI. To ad-
dress the impact of potential imbalance in prognostic
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factors we will repeat the primary analysis using the log-
rank test stratified by stage, age, family history of BC,
time since diagnosis, molecular subtype, medication use,
smoking, baseline waist circumference and dietary vari-
ables (baseline GI, dietary fiber, saturated fat, vegetables/
fruit, meat, sweets/desserts). Missing data for covariates
will be handled by using the missing indicator method.
Sensitivity analyses
To assess the robustness of our ITT primary analysis
with possible missing data we will repeat the primary
analysis using completers data only as well as per-
protocol data only, using multiple imputation method to
generate missing data in the stratification step. To assess
the impact of participant-level factors on the primary
outcome we will examine DFS separately in those who,
at study end, have reached normo-glycemia (<110 mg/
dl) and normal levels of HbA1c <6.0% versus those who
have higher levels, in those who reached circulating
25(OH)D ≥60 ng/ml versus those who reached ≤30 ng/
ml, in those who have lower versus those who have
higher insulin levels (median will be used as cut-offs), in
those who have good overall compliance on the three
treatment components that is in the highest quantile of:
low GI + number of daily steps + levels of 25(OH)D, ver-
sus those who have lower compliance. For these analyses
study end is defined as the mean of the last three visits.
Secondary analyses
The mean and standard error for each of the following
variables will be determined for each study group. The
change from baseline to end of study will be compared
between groups using repeated measures ANOVA and
using nonparametric tests if necessary, for the following
variables: body weight, waist circumference, BMI, blood
pressure, serum levels of 25(OH)D, blood glucose,
HbA1c, insulin, IGF-1, lipids, CRP, estradiol, testoster-
one, SHBG, specific microRNAs, dietary glycemic index,
number of steps per day and quality of life. We will also
test treatment differences in medication use and medica-
tion side effects. Chi-square test will be used to compare
categorical variables and Student t-test or Wilcoxon test
for continuous variables. The association between each
variable and prognosis will be analyzed using Cox pro-
portional hazard model and logistic regression. Finally,
we will assess whether these secondary analyses are dif-
ferent at year 1 compared to end of study. All statistical
analyses will be conducted with SPSS statistical software
version 23.0 (SPSS Inc., Chicago IL, USA).
Potential toxicity and adverse events
Toxicity due to diet, moderate exercise or vitamin D
supplementation are not expected. The diet is an en-
hanced Mediterranean diet with one arm consuming
more low GI foods and physical activity involves moder-
ate exercise of 30 min of daily brisk walk and both re-
spond to lifestyle principles suggested by cancer
guidelines such as the American Cancer Society [8] and
the World Cancer Research Fund [9]. Oral vitamin D
(cholecalciferol) supplementation will be given at safe
dosages (up to 4000 IU/day) to reach safe blood levels
(60 ng/ml for the test arm and 30 ng/ml for the control
arm) [53, 54]. In Italy the normal range of 25(OH)D is
between 30-100 ng/ml. Excess vitamin D levels
(>100 ng/ml) could induce excess calcium absorption
from the intestine and potentially result in hypercalce-
mia (>11 mg/dl). Both serum 25(OH)D and calcium
levels are monitored throughout the study at each clinic
visit and any signs or symptom of hypervitaminosis D
(hypercalcemia, excess thirst, etc.) will be recorded and
immediately communicated to the participant’s physician
and supplementation stopped. All adverse events occur-
ring after signing the consent form will be recorded in a
specific Adverse Event Form.
Ethical considerations
The study will determine which group will benefit the
most however both treatments are expected to gain
some health benefits since both treatments are based on
a healthy diet and lifestyle and sufficient vitamin D
levels. An interim analysis will be conducted to evaluate
whether there are excessive disadvantages for one group
over the other. Should this happen the study would be
terminated and both groups allowed to follow the most
beneficial treatment program. Participants health com-
plications will be dealt by the research team of doctors
and by contacting patients’ physicians. Should any com-
plication put the participant at risk by continuing the
study the participant will be invited to withdraw from
the study. The study participants will also have the right
to withdraw from the study anytime and for any per-
sonal reason without jeopardizing their health care in
the study institution or any other institution.
Discussion
The purpose of this study is to reduce BC recurrence
and hence increase disease-free survival through a life-
style program that includes a low glycemic index diet,
physical activity and vitamin D supplementation in
women with BC living in a Mediterranean country. It is
expected that the higher intensity program of low GI
diet, exercise and vitamin D will reduce BC recurrence
by 50% compared to the lower intensity program.
Dietary clinical trials to reduce BC recurrence have
been conducted previously. In the USA two large studies
were conducted, the Women’s Intervention Nutrition
trial (WIN) and the Women’s Healthy Eating and Living
trial (WHEL). The WIN study which focused on a low-
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fat diet found a 24% reduction in BC recurrence after
5 years compared to a control of minimal dietary coun-
selling [10], whereas the WHEL study focusing on a
combination of low-fat and high-fruit and -vegetable diet
did not reduce BC recurrence after a 7-year intervention
compared to a lower intensity fruit and vegetables advice
[11]. This null result may be partly explained by meth-
odology aspects as most women had early stage BC and
one of the inclusion criteria was the diagnosis of BC
within 4 years. It is possible that such a diet may be pro-
tective if consumed earlier, possibly within 1 year of
diagnosis as in the WIN study [10]. However, in the
WHEL study, women who at baseline consumed more
than 3 servings of vegetables per day showed a 30% re-
duction in BC recurrence and an even greater reduction
(up to 52%) in tamoxifen users [55]. Furthermore,
women who at baseline consumed at least 5 portions of
vegetables/fruit per day and additionally walked for at
least 30 min a day had a 44% higher chance of survival,
independently of obesity, suggesting that obesity did not
impact on lowering survival if people adhered to a
healthy lifestyle pattern [56]. Overall these large clinical
trials suggest the importance of intervening early after
diagnosis and that plant-based diets and half hour daily
walk may be protective from future recurrence. The low
fat advice may however be appropriate only in countries
with high intakes of saturated fat. In Mediterranean
countries where diets are characterized by high intakes
of olive oil, reducing fat intakes may not be beneficial. In
the PREDIMED intervention trial, women without BC
but following the intensive Mediterranean dietary advice
with high olive oil intakes showed up to 68% lower risk
of BC compared with those on lower olive oil intake
[57]. The traditional Mediterranean diet, rich in plant
food and olive oil, has been associated with protection
from BC risk [58, 59] CVD events [60], type two dia-
betes risk [61] and complications [62, 63] and favour
weight loss [64]. However, adherence to a traditional
Mediterranean diet has halved from the 60’s to 2003 in
Mediterranean countries including Italy [65], hence
there may be health benefits in improving the current
Mediterranean style dietary pattern. The Italian diet is
very rich in carbohydrates, particularly bread and other
fast absorbing carbohydrates (high GI foods) which have
been associated with higher risk of BC as well as
other chronic conditions [15, 16, 18, 66]. Since factors
influencing the metabolism of glucose may play a
relevant role in the development of chronic diseases
including BC [15], it is possible that lowering the GI of
the Mediterranean diet of Italian women with BC through
guided dietary advice, a lower recurrence may be achieved.
Chronic elevation of insulin concentrations may be one of
the mechanisms explaining the positive association be-
tween dietary GI and cancer risk [67]. High GI diets
increase blood glucose and insulin levels more than low
GI diets and hence may be involved in increasing IGF-1
bioavailability [31]. Insulin is an anabolic hormone able to
increase IGF-1 synthesis and activity and IGF-1 in turn
may promote cancer development by inhibiting apoptosis,
stimulating cell proliferation and sex-steroid synthesis
[68, 69]. Another mechanism for high GI-related in-
creased cancer risk may be through hyperglycemia-in-
duced oxidative stress [70, 71] which has been implicated
in free radical-dependent DNA damage, known as a con-
tributor to carcinogenesis [72, 73]. Within normal ranges
of glycemia higher levels of normal have been directly as-
sociated with BC risk in previously healthy women [74]
and with higher recurrence rates in women with BC [75].
Another potential mechanism may be through lowering
the availability of circulating glucose following low GI di-
ets and exercise. Cancer cells are avid consumers of
glucose due to their altered metabolism characterized
by insufficient oxidative phosphorylation and compen-
satory glucose fermentation (the Warburg effect) [76].
This results in lactic acid production and higher pro-
tons which acidify the external cellular microenviron-
ment reaching a pH of 6.5-6.9 [77]. A lower pH may
provide a competing survival and metastatic advan-
tage for cancer cells (e.g. greater spreading capacity)
over normal cells unable to survive below a pH of 7.2
[77, 78] and may induce drug resistance of weak
base-anticancer drugs (e.g. doxorubicin) [78].
Physical activity after BC diagnosis has also been
shown to reduce the risk of BC mortality by 40-50% par-
ticularly when it is of moderate intensity such as 30 mi-
nutes of brisk walking per day [32–35]. This effect may
be modulated partly by reduced insulin, insulin-like
growth factors and estrogen levels [36, 79, 80] which are
associated with BC recurrence and death [81, 82]. Fur-
thermore, physical activity can improve insulin sensitiv-
ity, reduce blood triglycerides, blood pressure and body
fat [83–85]. The lifestyle changes proposed in this study
(lower dietary GI, enhanced Mediterranean diet, physical
activity) may also induce weight loss which in turn may
improve insulin sensitivity, IGF profile and reduce aro-
matase activity in adipose tissue with consequent reduc-
tion in estrogen levels [86], particularly relevant in
postmenopausal women [87]. Although weight loss is
not a goal of the DEDiCa study, participants will be
allowed to lose weight in situations of overwheight or
obesity should they wish to. The secondary statistical
analyses will take into consideration this aspect.
Lifestyle changes may be more efficacious in a setting
of vitamin D sufficiency. Vitamin D alters genes impli-
cated in cellular growth, through upregulation of E-
cadherin thereby stimulating cell differentiation and
apoptosis [39]. Higher serum vitamin D levels (>30 ng/
ml) in BC patients have been associated with 50% less
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fatality rates compared to lower levels (<20 ng/ml) [88].
The vitamin D dose–response relationship for BC ap-
pears inverse and linear up to 60 ng/ml [39]. These
levels could achieve a 25% lower BC incidence and could
be reached by supplementing 2000–4000 IU/day [53,
89]. The upper dose recommended by the National
Academy of Sciences is 4000 IU/day [54]. The Italian
guidelines for the prevention and treatment of hypovita-
minosis D (SIOMMMS) indicate that in Italy this condi-
tion is present in 50% of young adults and at higher
rates in older individuals [53]. The updated SIOMMMS
guidelines for vitamin D deficiency (25-OH-D < 10 ng/
ml) suggest up to 600,000 as a cumulative dose [90]. In
Italy the normal range for circulating 25-OH-D is set be-
tween 30 ng/ml and 100 ng/ml while toxicity levels are
considered above 150 ng/ml [53]. Vitamin D can also
protect against bone loss and risk of fractures as a con-
sequence of osteoporosis typically seen after postmeno-
pause or after estrogen deprivation therapy used in BC
treatment. Hence vitamin D supplementation may also
reduce adverse skeletal effects [53]. Furthermore, higher
vitamin D levels have also been associated with reduced
risk of developing diabetes [91, 92]. Continuous im-
provements in survival rates will have an impact on
comorbidities and quality of life of BC survivors. Co-
morbid conditions have been found at higher preva-
lence in cancer survivors than in age-matched
controls [93] and in the subgroup of cancer patients
presenting with two comorbidities, the most frequent
combination of diseases appeared to be CVD in men
and diabetes in women [94]. There are downstream
effects of cancer therapy (e.g. radiation and chemo-
therapy) causing heart, respiratory, kidney and mem-
ory problems but also of hormone suppressing
therapy in BC patients [95]. Compounding on this
problem, cancer survivors fail to receive the same
level of care for their comorbid condition compared
to the general population [96] and this is especially
true for type two diabetes [97]. Hence it may become
even more relevant to implement cost-effective life-
style risk reduction strategies. Two international can-
cer organizations have published lifestyle guidelines
for cancer survivors, The American Cancer Society
(ACS) [8] and the World Cancer Research Fund
(WCRF) [9], however there is no agreement on a spe-
cific lifestyle program that could reduce BC recur-
rence and complications including recommendations
on vitamin D supplementation.
DEDiCa study includes treatment components such as
low GI, traditional Mediterranean foods, high dietary
fiber and physical activity which have been shown to re-
duce risk factors for type two diabetes and CVD includ-
ing HbA1c, blood glucose and lipids, and inflammatory
factors [15, 20, 22, 23, 25–28, 30, 60, 98–100].
This study will contribute to understanding the ef-
ficacy of lifestyle changes in a Mediterranean popula-
tion of BC survivors with respect to several novel
aspects: testing a lifestyle modification (diet and ex-
ercise) within normal vitamin D levels on disease-
free survival; investigate lifestyle changes in relation
to BC staging, molecular subtypes, menopausal sta-
tus, body weight, CVD risk factors and events, dia-
betes control, new diabetes cases, quality of life,
response to medication. It will also allow to under-
stand breast carcinogenesis and the role of micro-
RNA in BC and whether they are modulated by
dietary and other lifestyle aspects. It will allow to in-
vestigate best time of treatment adherence since
women will be enrolled within 12 months of surgery,
some will have just started their cancer therapy and
some will have ended.
Given the supporting evidence of important health ef-
fects and safety of the components of DEDiCa interven-
tion we believe it is feasible and urgent to test this
program in BC patients.
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